Page 7 - மீடியா பிரான்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Poxel SA: Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced its participation at the Mitochondria-Targeted Drug Development Summit (April 27-29). On April 29, Sophie Bozec, PhD, Senior Vice President, R&D Pharmacology and Scientific Communication, and Co-Founder of Poxel is presenting a talk entitled Mitochondrial Dysfunction in Metabolic Diseases during the session - Clinical Stage Molecules Targeting Mitochondrial Mechanisms. The presentation highlights Poxel s scientific focus and deep expertise in mechanisms which modulate cellular energy homeostasis and address mitochondrial dysfunction.

United statesSouth koreaSumitomo dainippon pharmaArthur rouillValeria fisherCatherine davidSophie bozecDrug development summitWorld health organizationDevices agencyTrophic communicationsMitochondria targeted drug development summitSenior vice presidentScientific communicationClinical stage molecules targeting mitochondrialSoutheast asian